Biosimilars Ineligible For Reduced Medicaid Rebates As Authorized Generics
Executive Summary
CMS reiterates and elaborates on its position that biosimilars should be subject to brand-level rebates in Medicaid, adding to the perception that the agency’s reimbursement policies do not promote development of biosimilars.